Safety and efficacy of SARS-CoV-2 vaccination in patients with immune thrombocytopenia: A two-centre review

Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS-CoV-2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS-CoV-2 vaccination doses were included in th...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2024-01, Vol.204 (1), p.324-328
Main Authors: Stefani, Sara, Buti, Noora, Hart, Alice C J, Paul, Deena, Rizvi, Naghma, Ragoonanan, Vashti, Vladescu, Camelia, Szydlo, Richard, Ademokun, Christine, Jansen, A J Gerard, Cooper, Nichola
Format: Article
Language:English
Subjects:
Antibodies, Viral
Antibody response
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Hematology
Humans
Idiopathic thrombocytopenic purpura
Purpura, Thrombocytopenic, Idiopathic - complications
Recurrence
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple studies have reported immune thrombocytopenia (ITP) relapse following SARS-CoV-2 vaccination, however baseline ITP relapse rate and antibody response to vaccination are not known. Patients with ITP who received at least one of the first three SARS-CoV-2 vaccination doses were included in the study. One hundred and twenty-four patients met the inclusion criteria. Relapse rate was 4.2% following a first vaccine dose, 9.1% after a second and 2.9% after a third; baseline relapse rate was 7.6%. Ninety-four per cent of patients who received three vaccine doses developed a clinical antibody response. SARS-CoV-2 vaccination appears to be safe and effective in patients with ITP.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.19212